[{"address1": "21 Ha\u2019arba\u2019a Street", "city": "Tel Aviv", "zip": "6473921", "country": "Israel", "phone": "972 3 541 3131", "fax": "972 3 541 3144", "website": "https://www.redhillbio.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Mr. Dror  Ben-Asher", "age": 58, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 566465, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Razi  Ingber", "age": 40, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2024, "totalPay": 349508, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adi  Frish", "age": 54, "title": "Chief Corporate & Business Development Officer", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 322592, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rick D. Scruggs", "age": 64, "title": "Chief Commercial Officer & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 443736, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gilead  Raday MPhil, MSc", "age": 49, "title": "Chief Operating Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 365556, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark L. Levitt M.D., Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Okmian", "title": "Senior Business Development & Investor Relations Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Reza  Fathi Ph.D.", "age": 69, "title": "Senior Vice President of Research & Development", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 299291, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Guy  Goldberg J.D.", "age": 48, "title": "Chief Business Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 338126, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Patricia  Anderson B.Sc. RAC", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.035, "open": 1.03, "dayLow": 1.03, "dayHigh": 1.07, "regularMarketPreviousClose": 1.035, "regularMarketOpen": 1.03, "regularMarketDayLow": 1.03, "regularMarketDayHigh": 1.07, "payoutRatio": 0.0, "beta": 4.821, "trailingPE": "Infinity", "forwardPE": 35.666668, "volume": 77923, "regularMarketVolume": 77923, "averageVolume": 1819782, "averageVolume10days": 108290, "averageDailyVolume10Day": 108290, "bid": 1.01, "ask": 1.09, "bidSize": 1, "askSize": 1, "marketCap": 3562947, "fiftyTwoWeekLow": 1.01, "fiftyTwoWeekHigh": 8.75, "allTimeHigh": 22220.0, "allTimeLow": 1.01, "priceToSalesTrailing12Months": 0.37308344, "fiftyDayAverage": 1.5398, "twoHundredDayAverage": 2.10022, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 19289458688, "profitMargins": -0.97518, "floatShares": 16654500537, "sharesOutstanding": 3329857, "sharesShort": 179078, "sharesShortPriorMonth": 699566, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.0538, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.028099999, "shortRatio": 0.15, "shortPercentOfFloat": 0.0582, "impliedSharesOutstanding": 3329857, "bookValue": -2.447, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -9313000, "trailingEps": 0.0, "forwardEps": 0.03, "lastSplitFactor": "1:25", "lastSplitDate": 1724112000, "enterpriseToRevenue": 2019.839, "enterpriseToEbitda": -2313.995, "52WeekChange": -0.8628205, "SandP52WeekChange": 0.1028198, "quoteType": "EQUITY", "currentPrice": 1.07, "recommendationKey": "none", "totalCash": 2866000, "totalCashPerShare": 0.0, "ebitda": -8336000, "totalDebt": 214000, "quickRatio": 0.369, "currentRatio": 0.563, "totalRevenue": 9550000, "revenuePerShare": 6.178, "returnOnAssets": -0.25322, "grossProfits": 6155000, "freeCashflow": -4080000, "operatingCashflow": -8199000, "revenueGrowth": 0.586, "grossMargins": 0.64449996, "ebitdaMargins": -0.87288004, "operatingMargins": -1.0733, "financialCurrency": "USD", "symbol": "RDHL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "RedHill Biopharma Ltd.", "marketState": "CLOSED", "postMarketChangePercent": -2.813094, "postMarketPrice": 1.0399, "postMarketChange": -0.030100107, "regularMarketChange": 0.0350001, "regularMarketDayRange": "1.03 - 1.07", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1819782, "fiftyTwoWeekLowChange": 0.060000062, "fiftyTwoWeekLowChangePercent": 0.059406, "fiftyTwoWeekRange": "1.01 - 8.75", "fiftyTwoWeekHighChange": -7.68, "fiftyTwoWeekHighChangePercent": -0.8777143, "fiftyTwoWeekChangePercent": -86.28205, "earningsTimestampStart": 1744282805, "earningsTimestampEnd": 1744282805, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 0.0, "epsForward": 0.03, "fiftyDayAverageChange": -0.4698, "fiftyDayAverageChangePercent": -0.30510455, "twoHundredDayAverageChange": -1.0302199, "twoHundredDayAverageChangePercent": -0.49052954, "priceToBook": -0.43727013, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1357569000000, "cryptoTradeable": false, "shortName": "Redhill Biopharma Ltd.", "corporateActions": [], "postMarketTime": 1763770667, "regularMarketTime": 1763758801, "exchange": "NCM", "messageBoardId": "finmb_104926324", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.38165, "regularMarketPrice": 1.07, "displayName": "RedHill Biopharma", "trailingPegRatio": null, "__fetch_time": "2025-11-22"}]